Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -45

Novo wants to change how Wall Street owns its stock: why now

AI-generated analysis

🏢 Novo Nordisk is exploring a switch from ADRs to a direct NYSE listing to boost its profile in the US market, where 56% of sales are generated.

📉 Shares fell approximately 8% after a capital markets day failed to reassure investors about the company's medium-term growth ambitions amidst fierce competition.

💊 CEO Mike Doustdar emphasized that while oral treatments could capture up to 50% of the global obesity market by 2030, the strategy must overcome challenges from Eli Lilly's injectable dominance.

📅 Novo plans to launch at least five potential blockbuster medicines by 2030 and generate over DKK150 billion in risk-adjusted pipeline sales by 2035.

⚠️ Analysts warn that semaglutide could still represent nearly 60% of sales in 2031, highlighting the critical need for successful diversification beyond the current blockbuster molecule.

📉 Morgan Stanley downgraded Novo Nordisk to Underweight, arguing the valuation does not fully reflect subdued growth expectations and the implications of the patent cliff.

🔮 Analyst forecasts predict only 2% to 3% revenue growth in 2027 and roughly 4% annual growth from 2027 through 2030, reflecting cautious market sentiment.

📊 AlphaValue analyst Abhishek Raval maintains a Buy rating but calls for aggressive diversification bets alongside strong commercial execution to reduce dependence on one molecule.

🏛️ A direct listing could improve visibility and liquidity but cannot by itself repair confidence in Novo's growth trajectory or replace future semaglutide revenue.

Bullish Signals
  • US operations generate about 56% of the group's sales, making American investors central to the company's future growth strategy.
  • CEO Mike Doustdar projects that oral treatments could account for as much as 50% of the global obesity-drug market by 2030, significantly above current Wall Street forecasts.
  • Novo outlined plans to launch at least five potential blockbuster medicines by 2030 and generate more than DKK150 billion in risk-adjusted pipeline sales by 2035.
Risk Factors
  • Shares fell about 8% as investors questioned a medium-term growth ambition closer to the broader pharmaceutical industry than the exceptional expansion Novo once delivered.
  • Morgan Stanley recently downgraded Novo Nordisk to Underweight, arguing that its valuation does not entirely reflect subdued medium-term growth or the implications of the semaglutide patent cliff.
  • Analysts forecast only 2% to 3% revenue and EBIT growth in 2027 and roughly 4% annual growth from 2027 through 2030, indicating cautious expectations for future performance.
  • The company faces a looming patent cliff where semaglutide could still represent 59% of sales in 2031 when loss-of-exclusivity effects begin to emerge.
Full Analysis
Novo Nordisk is considering replacing its American Depositary Receipts (ADRs) with a direct listing on the New York Stock Exchange to enhance its profile among US investors, though the company states it is not actively pursuing this change. CEO Mike Doustdar highlighted that US operations currently generate approximately 56% of the group's sales, making American market visibility critical as the company faces intensifying competition from Eli Lilly in the obesity drug sector. The strategic discussion comes amidst investor concerns regarding Novo's growth trajectory following a recent capital markets day where shares fell about 8%. While Novo outlined plans to launch at least five potential blockbuster medicines by 2030 and generate over DKK150 billion in pipeline sales, analysts warn that the company remains heavily dependent on semaglutide, which could still represent nearly 60% of sales even after patent exclusivity begins to wane. Wall Street analysts have downgraded Novo Nordisk due to fears that its medium-term growth ambitions are too conservative compared to the exceptional expansion seen previously. Morgan Stanley recently lowered its rating to Underweight, citing a valuation that does not fully reflect subdued growth expectations and the looming patent cliff. Consequently, while a direct listing might improve liquidity and visibility, it is viewed as secondary to the core investment questions of pipeline diversification and execution against competitors like Eli Lilly.